Abstract:Tau phosphorylation at specific Alzheimer's disease (AD)‐relevant epitopes negatively affects mitochondria, with the extent of dysfunction and stress response varying according to the sites of phosphorylation. ATP levels were reduced in cells expressing either tau pseudophosphorylated at S396/404 (2EC) or T231/S235 (2EM), and ROS production increased in 2EC cells during oxidation of succinate compared to wild type (T4)‐expressing cells. Thapsigargin reduced mitochondrial membrane potential (Ψm) and increased ROS production in both 2EC and 2EM cells. Altogether, these findings extend our understanding of potential mechanisms whereby phosphorylated tau promotes mitochondria dysfunction in tauopathies, including AD. The thickness of the green arrows corresponds with the magnitude of effect. The longer red and black arrows represent experiments conducted with stressors and in the basal state, respectively. Phosphorylation of tau at sites associated with Alzheimer's disease (AD) likely plays a role in the disease progression. Mitochondrial impairment, correlating with increased presence of phosphorylated tau, has been identified as a contributing factor to neurodegenerative processes in AD. However, how tau phosphorylated at specific sites impacts mitochondrial function has not been fully defined. We examined how AD‐relevant phosphomimetics of tau impact selected aspects of mitochondrial biology. To mimic phosphorylation at AD‐associated sites, the serine/threonine (Ser/Thr) sites in wild‐type green fluorescent protein (GFP)‐tagged tau (T4) were converted to glutamic acid (E) to make pseudo‐phosphorylated GFP‐tagged Ser‐396/404 (2EC) and GFP‐tagged Thr‐231/Ser‐235 (2EM) constructs. These constructs were expressed in immortalized mouse hippocampal neuronal cell lines, and their impact on specific mitochondrial functions and responses to stressors were measured. Phosphomimetic tau altered mitochondrial distribution. Specifically, mitochondria accumulated in the soma of cells expressing either 2EC or 2EM and neurite‐like extensions in 2EC cells were shorter. Additionally, adenosine triphosphate levels were reduced in both 2EC‐ and 2EM‐expressing cells, and reactive oxygen species (ROS) production increased in 2EC cells during oxidation of succinate when compared to T4‐expressing cells. Thapsigargin reduced mitochondrial membrane potential and increased ROS production in both 2EC and 2EM cells relative to T4 cells, with no significant difference in the effects of rotenone. These results show that tau phosphorylation at specific AD‐relevant epitopes negatively affects mitochondria, with the extent of dysfunction and stress response varying according to the sites of phosphorylation. Altogether, these findings show that phosphorylated tau increases mitochondrial susceptibility to stressors and extend our understanding of potential mechanisms whereby phosphorylated tau promotes mitochondria dysfunction in tauopathies, including AD.

Site-specific phosphorylation of tau inhibits amyloid-β toxicity in Alzheimer’s mice

Novel Cathepsin D Inhibitors Block the Formation of Hyperphosphorylated Tau Fragments in Hippocampus

Tau Protein Antagonizes Cell Apoptosis Through Akt Pathway

P3‐309: Overexpression of Hyperphosphorylated Tau Antagonizes Aβ‐potentiated Apoptosis with Preservation of Mitochondrial Elements

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

Protein tau phosphorylation in the proline rich region and its implication in the progression of Alzheimer's disease

Aggregation promoting sequences rather than phosphorylation are essential for Tau-mediated toxicity in

Site‐specific phosphorylation of tau impacts mitochondrial function and response to stressors

Reduction of advanced tau‐mediated memory deficits by the MAP kinase p38γ

Pathological Tau From Alzheimer's Brain Induces Site-Specific Hyperphosphorylation and SDS- and Reducing Agent-Resistant Aggregation of Tau in vivo .

Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ

β2 Adrenergic Receptor, Protein Kinase A (PKA) and c-Jun N-terminal Kinase (JNK) Signaling Pathways Mediate Tau Pathology in Alzheimer Disease Models

Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer's disease

Phosphorylation of Tau Antagonizes Apoptosis by Stabilizing Β-Catenin, a Mechanism Involved in Alzheimer's Neurodegeneration

Humanized Tau Mice with Regionalized Amyloid Exhibit Behavioral Deficits but No Pathological Interaction

Targeting Abnormal Tau Phosphorylation for Alzheimer's Therapeutics

Alzheimer’s disease: Ablating single master site abolishes tau hyperphosphorylation

Phosphorylation of tau at a single residue inhibits binding to the E3 ubiquitin ligase, CHIP

Amyloid-β-independent regulators of tau pathology in Alzheimer disease

Selective degradation of hyperphosphorylated tau by proteolysis-targeting chimeras ameliorates cognitive function in Alzheimer's disease model mice

Selective Degradation of Hyperphosphorylated Tau by Proteolysis-Targeting Chimeras Ameliorates Cognitive Function in Alzheimer’s Disease Model Mice